We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should continue to benefit from the addition of products acquired from Abbott Laboratories (February 2015), Pharmaq (November 2015), Nexvet (July 2017) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.
Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 4.54%.
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Zoetis reported earnings per share of 75 cents beating the Zacks Consensus Estimate of 70 cents in first-quarter of 2018.
Revenues Beat: Zoetis posted revenues of $1.37 billion slightly surpassing the Zacks consensus estimate of $1.33 billion.
Key Stats: During the first quarter, Zoetis received approval for swine vaccine, Fostera, in the United States. The company continued to expand the availability of companion animal products – Cytopoint received approval in Mexico & Switzerland and Simparica was approved in Thailand & Serbia. Several major cattle products, including Inforce 3 and Spectramast DC, also received approvals in new geographies.
2018 Outlook Reiterated: Zoetis maintained its outlook for 2018. In 2018, the company expects adjusted earnings in the range of $2.96 to $3.10 per share on revenues of $5.675 billion and $5.800 billion. The Zacks Consensus Estimate for earnings is $3.04 per share on revenues of $5.75 billion.
Share Price Impact: Shares of the company were up 0.1% in-pre-market trading.
Check back later for our full write up on this ZTS earnings report later!
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Zoetis (ZTS) Q1 Earnings & Revenues Surpass Estimates
Florham Park, NJ-based Zoetis Inc. (ZTS - Free Report) is one of the leading global animal health companies focused on the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
Zoetis’ diversified portfolio of products for livestock and companion animals should continue to drive top-line growth at the company. The company’s top line should continue to benefit from the addition of products acquired from Abbott Laboratories (February 2015), Pharmaq (November 2015), Nexvet (July 2017) as well as from the performance of Apoquel and other key brands. In this scenario, investor focus remains on top-and bottom-line numbers.
Zoetis’ track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis’ earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 4.54%.
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Zoetis reported earnings per share of 75 cents beating the Zacks Consensus Estimate of 70 cents in first-quarter of 2018.
Revenues Beat: Zoetis posted revenues of $1.37 billion slightly surpassing the Zacks consensus estimate of $1.33 billion.
Key Stats: During the first quarter, Zoetis received approval for swine vaccine, Fostera, in the United States. The company continued to expand the availability of companion animal products – Cytopoint received approval in Mexico & Switzerland and Simparica was approved in Thailand & Serbia. Several major cattle products, including Inforce 3 and Spectramast DC, also received approvals in new geographies.
2018 Outlook Reiterated: Zoetis maintained its outlook for 2018. In 2018, the company expects adjusted earnings in the range of $2.96 to $3.10 per share on revenues of $5.675 billion and $5.800 billion. The Zacks Consensus Estimate for earnings is $3.04 per share on revenues of $5.75 billion.
Share Price Impact: Shares of the company were up 0.1% in-pre-market trading.
Check back later for our full write up on this ZTS earnings report later!
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. Price and EPS Surprise | Zoetis Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>